Can-Fite BioPharma Ltd. Quarterly Deferred Tax Assets, Gross in USD from Q4 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Can-Fite BioPharma Ltd. quarterly Deferred Tax Assets, Gross history and growth rate from Q4 2018 to Q4 2023.
  • Can-Fite BioPharma Ltd. Deferred Tax Assets, Gross for the quarter ending December 31, 2023 was $26.7M, a 0.56% increase year-over-year.
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $26.7M +$149K +0.56% Dec 31, 2023 20-F 2024-03-28
Q4 2022 $26.5M -$2.12M -7.4% Dec 31, 2022 20-F 2024-03-28
Q4 2021 $28.6M -$7.26M -20.2% Dec 31, 2021 20-F 2023-03-30
Q4 2020 $35.9M +$6.36M +21.6% Dec 31, 2020 20-F 2022-03-24
Q4 2019 $29.5M +$5.2M +21.4% Dec 31, 2019 20-F 2021-03-25
Q4 2018 $24.3M Dec 31, 2018 6-K 2020-06-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.